On May 2, 2017, Biostar Stem Cell Research Institute (CEO- Jeong-chan Ra), co-operated by Nature Cell and R-Bio, appointed Hong-gil Um, a renowned South Korean mountaineer, as an honorary ambassador to promote ‘JointStem,’ an autologous stem cell-based medicine for treating degenerative arthritis.
Read more
Biostar Stem Cell Research Institute , which is co-operated by NATURE CELL and R-bio, published that a third clinical center for the phases 1 and 2 of ‘AstroStem’, a stem cell drug for Alzheimer’s disease that is currently undergoing clinical trials following the approval from the U.S. FDA, has been additionally selected.
Read more
SEOUL, South Korea – Bio technology enterprise Nature Cell (KOSDAQ: 007390) announced that it had started to recruit patients for its clinical trials of ‘ASTROSTEM,’ an stem cell drug for Alzheimer disease treatment, in the U.S.
Read more
According to the Regenerative Medical Act of Japan, which has been enforced since November 25, 2015, R-Japan, an affiliated with Nature Cell, got permission of Type 2 Specific Cell Artifact (stem-cell) from Japan’s Ministry of Health, Labor and Welfare, which is the only case among South Korean companies; R-Japan announced its business performance for 2016.
Read more
The stem cell treatment VASCOSTEM has been registered as the Orphan Drug in Development Phase.
Read more
On January 25th Biostar Stem Cell Research Institute, headed by Dr. Jeong Chan Ra, and jointly operated by Nature Cell and R Bio, has announced the registration of the Patent “Production Method of Stem Cells for Intravascular Administration” (Application number: 10-2012-0040488, 2012), with the European Patent Office.
Read more
Biostar Stem Cell Research Institute
08506
305, Lotte IT Castle Building #2, 550-1, Gasan-dong, Geumcheon-gu, Seoul
R Bio Co.,Ltd.
+82 -2-858-8021~5
Most Commented